We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

111 hedge funds and large institutions have $539M invested in Insys Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

53% more capital invested

Capital invested by funds: $352M → $539M (+$187M)

25% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 32

12% more funds holding

Funds holding: 99 → 111 (+12)

0% more call options, than puts

Call options by funds: $8.81M | Put options by funds: $8.8M

Holders
111
Holders Change
+12
Holders Change %
+12.12%
% of All Funds
3.22%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
28
Increased
40
Reduced
32
Closed
16
Calls
$8.81M
Puts
$8.8M
Net Calls
+$15K
Net Calls Change
+$1.66M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$23.1M
2
Millennium Management
Millennium Management
New York
+$20.7M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$15.9M
4
EAM
EverPoint Asset Management
Connecticut
+$14.9M
5
JHIU
Janus Henderson Investors US
Colorado
+$10M

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$10.4M
2
BTP
Bloom Tree Partners
New York
-$7.85M
3
BG
BlackRock Group
United Kingdom
-$6.36M
4
PP
PDT Partners
New York
-$5.22M
5
Morgan Stanley
Morgan Stanley
New York
-$3.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
TDC
101
Thompson Davis & Co
Virginia
$10K +$7.85K +500 New
US Bancorp
102
US Bancorp
Minnesota
$10K +$7.85K +500 New
BlackRock
103
BlackRock
New York
$9K – – –
GC
104
Globeflex Capital
California
$3K -$2.26K -144 -45%
NFG
105
Next Financial Group
Texas
$3K – – –
PFG
106
Piershale Financial Group
Illinois
$3K +$785 +50 +50%
Ameriprise
107
Ameriprise
Minnesota
$1K – – –
ST
108
Spot Trading
Illinois
$1K +$502 +32 New
Manulife (Manufacturers Life Insurance)
109
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$287 +$6.12K +390 +3%
CIA
110
Capital Impact Advisors
Massachusetts
$252 – – –
KBC Group
111
KBC Group
Belgium
– -$2.26M -144,566 Closed
MWVC
112
Morgens Waterfall Vintiadis & Co
New York
– -$1.87M -120,000 Closed
TI
113
Turner Investments
Pennsylvania
– -$1.74M -111,460 Closed
GAM
114
Gotham Asset Management
New York
– -$940K -60,222 Closed
HT
115
HAP Trading
New York
– -$835K -53,500 Closed
Alyeska Investment Group
116
Alyeska Investment Group
Illinois
– -$686K -43,914 Closed
ARC
117
Absolute Return Capital
Massachusetts
– -$316K -20,230 Closed
OC
118
Oppenheimer & Co
New York
– -$307K -19,624 Closed
EMG
119
Ellington Management Group
Connecticut
– -$287K -18,400 Closed
MCTIC
120
MacGuire Cheswick & Tuttle Investment Counsel
Connecticut
– -$243K -15,568 Closed
NA
121
Navellier & Associates
Nevada
– -$208K -13,300 Closed
QT
122
Quantbot Technologies
New York
– -$49K -3,200 Closed
VFA
123
Virtus Fund Advisers
Connecticut
– -$27K -1,704 Closed
WA
124
WealthTrust-Arizona
Arizona
– -$9K -600 Closed
RIA
125
Regal Investment Advisors
Michigan
– -$6K -360 Closed
2 3 4
5
6

INSY Hedge Fund Activity: Q3 2014 in Review

111 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2014, worth a combined $539M — up 53% from $352M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new INSY positions and 16 closed out — a net gain of 12 holders — while 40 added to existing stakes and 32 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $23.1M. The largest seller was BlackRock Advisors, cutting an estimated $10.4M.

  • 111 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2014, up from 99 in Q2 2014.
  • Funds reported $539M of Insys Therapeutics, Inc. stock for Q3 2014, up 53% quarter-over-quarter.
  • 28 funds opened new Insys Therapeutics, Inc. positions in Q3 2014 and 16 closed out, a net change of +12 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q3 2014 was OrbiMed, an estimated $23.1M added.
  • The largest Insys Therapeutics, Inc. seller in Q3 2014 was BlackRock Advisors, an estimated $10.4M sold.

Based on aggregated 13F filings for Q3 2014.